Pharma: Are generics still ailing? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Are generics still ailing?

Feb 20, 2006

The year gone by (2005) will be a year that Indian pharma companies will want to forget, but will not be able to do so. Besides VAT-related concerns, what really plagued the domestic companies was the unprecedented pricing pressure witnessed in the key generics markets of the US and Europe. The generics market a couple of years back was a lucrative one for Indian companies such as Ranbaxy and Dr.Reddy's, which were one of the earlier entrants in the market, besides global majors like Teva (Israel) and Sandoz. However, since then, the dynamics of the global generics industry has witnessed a sea change. The existing major players that had captured a significant market share a couple of years back, are today struggling to hold on to the same. This is because the next generation of pharma companies is jumping the generic bandwagon in a bid to boost revenues. These companies can only hope to capture a certain portion of the market by offering products at a lower price than the existing ones, leading to a downward spiral in overall price realisations. Add to this, the problem of 'authorised generics', which diffuse to a large extent, the benefits that a challenging generics company would have enjoyed had it been the only player in the market during the exclusivity period. So, what is it that will enable companies to establish a stronghold over the generics market and sustain revenues? We feel that a combination of these four factors will play a crucial role in maintaining a competitive advantage in the generics industry.

Scale: Growth through the inorganic route is the fastest way of acquiring scale, especially in markets in which a company's presence is minimal. Teva's acquisition of Ivax and Dr. Reddy's recent acquisition of Betapharm are testimony to this fact. This alleviates the need to make investments in the region right from scratch. At the same time, in the generics environment, the right acquisition target would be that company, which has a significant presence in more than one market, a deep product pipeline and an established marketing network. Currently, consolidation in the generics space is heating up in a bid to boost revenues and maintain margins. However, on the flipside, expensive valuations are an area of concern to be kept in mind.

Increased product launches: With increased competition, a large number of blockbuster molecules are facing price erosion upto as much as 90%. Even smaller molecules are facing the heat. However, despite this, launching of new products assumes importance to counter this pressure. While existing products will continue to face erosion, launch of new products will help maintain the balance. In 2005, a dearth of new product launches and price erosion of existing products contributed to the decline in revenues of domestic companies, chiefly Ranbaxy and Dr. Reddy's. Foraying into niche areas like injectables and biogenerics (Wockhardt and Biocon), where the competition is relatively lesser, is also another strategy to drive growth.

Cost competitiveness: The first rule to be followed by any generics company is to become cost competitive. While the scramble to capture market share intensifies the extent of erosion and puts a squeeze on margins, keeping a tight leash over costs will help maintain margins. India, being a low cost country, has that edge over its peers. However, global companies are aware of this fact and are increasingly shifting their base to Indian shores. Therefore, domestic companies cannot afford to lose out on the low cost advantage that India enjoys.

Geographical reach: In FY05, while Dr. Reddy's' US and European businesses witnessed a decline, it was the Russian markets that kept the company's ship from completely sinking. Similarly, in Ranbaxy's case, while the US business continues to remain a laggard, the European region and the semi-regulated markets of Russia, China and the like have contributed to revenues. Different countries have different competitive and regulatory environments. In such a scenario, geographical reach assumes importance, as difficult conditions in one particular market can be offset by a healthy performance in other markets.

What to expect?
Despite the difficult conditions faced by the Indian generics players, we believe that a significant number of patent expiries in the coming couple of years will drive growth in the generics market. Volumes rather than realisations will most likely drive this growth. While pricing pressure is expected to continue, the fundamentals driving this industry as such remain strong. However, while still a long-term play, a focus on developing proprietary drugs will also go a long way in easing the pressure. Teva's first proprietary drug generating revenues just under US$ 1 bn is a case in point. From a long-term perspective, we believe that domestic companies that besides generics, also focus on R&D, will be in a position to be a part of the big league. Thus, despite mounting pressures, we believe that the generics story is still not over!


Equitymaster requests your view! Post a comment on "Pharma: Are generics still ailing?". Click here!

  

More Views on News

Your Queries on the 8-Year Cycle Answered (Fast Profits Daily)

Sep 25, 2020

You've sent in your queries on my videos on the 8-year greed and fear cycle in the market. I'll answer them in this video.

It's When You Sell that Counts (Profit Hunter)

Sep 25, 2020

How I alerted readers to the impending crash last week.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

How to Save Money by Exiting Stocks Before They Fall podcast (Views On News)

Sep 24, 2020

A penny saved is a penny earned. It doesn't matter where you enter. All that matter is where you exit. Watch this video to identify an opportune time to exit your investments and book profits.

ICICI Prudential ESG Fund: Aims for Sustainability (Outside View)

Sep 24, 2020

PersonalFN briefly explains the newly launched fund : ICICI Prudential ESG Fund.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Sep 25, 2020 (Close)

MARKET STATS